Announcement no. 14/2007
To OMX Nordic Exchange Hørsholm, Denmark, 1 June 2007
LifeCycle Pharma A/S' total capital and the total number of voting rights
Hørsholm, Denmark, 1 June 2007; In accordance with section 17 (2) of the Danish
Executive Order no. 226 of March 15, 2007 on the issuers' disclosure
requirements, LifeCycle Pharma A/S (OMX:LCP) hereby informs that the total share
capital of LifeCycle Pharma A/S amounts to DKK 30,514,048 consisting of
30,514,048 shares each of a nominal value of DKK 1. Each share of nominal value
DKK 1 carries one voting right. Accordingly, the total number of voting rights
is 30,514,048.
For further information please contact:
LifeCycle Pharma A/S
Michael Wolff Jensen
Executive Vice President and CFO
Tel. +45 40 74 62 44
---oo0oo---
About LifeCycle Pharma A/S:
LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging
pharmaceutical company with a broad and late stage product pipeline in
therapeutic areas of cholesterol management, hypertension, organ transplant and
autoimmune diseases. LifeCycle Pharma's proprietary technology platform,
MeltDose® technology, offers lower dosing, reduced side effects and improved
safety and patient compliance, as well as reduced product development time and
development costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under
the trading symbol (LCP). Please visit www.lcpharma.com for further information
about LifeCycle Pharma A/S.
LifeCycle Pharma A/S' total capital and the total number of voting rights
| Quelle: Veloxis Pharmaceuticals A/S
Anhänge
